The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Thrombus Imaging With Fibrin-Specific Gadolinium-Based MR Contrast Agent EP-2104R: Results of a Phase II Clinical Study of Feasibility
Abstract
PURPOSE: To determine the feasibility of detecting thrombi using a fibrin-specific gadolinium-based magnetic resonance imaging contrast agent, EP-2104R. METHODS: Subjects with confirmed thrombus in the venous system (n = 14), or in the heart, or arterial system (n = 38) were enrolled. Patients were imaged before and at various times following a 4 mumol/kg intravenous bolus injection of EP-2104R: <1 hour (N = 16), 2 to 6 hours (N = 36), and/or 20 to 36 hours (N = 33). Images were assessed by investigators at each site and by a single reader not affiliated with the sites to determine whether thrombi were visible, not visible, or further enhanced with EP-2104R. A subset of data was analyzed quantitatively by measuring a signal intensity relative to background tissue. RESULTS: Overall, 29 thrombi were visible before contrast administration, 3 of 14 in the venous system, and 26 of 38 in the arteries and heart. Thrombi generally enhanced in signal after EP-2104R injection, and an additional 7 were visualized. After contrast, 4 of 14 thrombi were visible in the venous system, and 32 of 38 in the arteries and heart. Thrombi were more conspicuous when imaged at 2 to 6 hours post EP-2104R compared with within 1 hour, because of lower blood background. Quantitatively, the post: pre signal intensity ratio was 1.90 at 2 to 6 hours post injection (standard deviation = 1.08, N = 20, P < 0.001); and 2.04 (standard deviation = 1.29, N = 19, P < 0.0025) for the 20 to 36 hours time point. There were no serious adverse events considered related to study drug. CONCLUSION: EP-2104R enhanced magnetic resonance imaging detects thrombi not readily visible in precontrast screening and gives additional enhancement of thrombi that are visible in precontrast imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Cited by
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
Self-citation25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives
Lohrke, J., Frenzel, T., Endrikat, J., Alves, F. C., Grist, T. M., Law, M., Lee, J. M., Leiner, T., Li, K.-C., Nikolaou, K., et al. (2016) · Advances in Therapy · doi:10.1007/s12325-015-0275-4 · Cited by 420
A Manganese Alternative to Gadolinium for MRI Contrast
Gale, E. M., Atanasova, I. P., Blasi, F., Ay, I., & Caravan, P. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b10748 · Cited by 353
Self-citationSmall animal cardiovascular MR imaging and spectroscopy
Bakermans, A. J., Abdurrachim, D., Moonen, R. P. M., Motaal, A. G., Prompers, J. J., Strijkers, G. J., Vandoorne, K., & Nicolay, K. (2015) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2015.03.001 · Cited by 35
Metadata
- Authors
- Vymazal, J., Spuentrup, E., Cardenas-Molina, G., Wiethoff, A. J., Hartmann, M. G., Caravan, P., & Parsons, E. C.
- Venue
- Investigative Radiology
- Published
- 2009-11
- Volume
- 44
- Issue
- 11
- Pages
- 697-704
- ISSN
- 0020-9996 (ISSN-L)
- OpenAlex
- W2073892627
- Cited by
- 167
- References
- 1
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombus Imaging With Fibrin-Specific Gadolinium-Based MR Contrast Agent EP-2104R: Results of a Phase II Clinical Study of Feasibility. https://app.cochat.ai/papers/10.1097/rli.0b013e3181b092a7
- The paper
- Vymazal, J., Spuentrup, E., Cardenas-Molina, G., Wiethoff, A. J., Hartmann, M. G., Caravan, P., & Parsons, E. C. (2009). Thrombus Imaging With Fibrin-Specific Gadolinium-Based MR Contrast Agent EP-2104R: Results of a Phase II Clinical Study of Feasibility. Investigative Radiology. https://doi.org/10.1097/rli.0b013e3181b092a7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.